Haystack Oncology uses the next generation of circulating tumor DNA (ctDNA) detection technology to see through the noise and uncover the lowest levels of ctDNA in blood to report residual, recurrent, or resistant disease earlier than any other minimal residual disease (MRD) test. Designed by cancer genomics pioneers and liquid biopsy experts, Haystack's tumor-informed MRD test is best positioned to deliver the right treatment to the right person at the right time. Haystack is based in Baltimore, MD, USA, and has research facilities in Hamburg, Germany.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/16/22 | $56,000,000 | Series A |
Bruker Corporation Catalio Capital  Exact Ventures | undisclosed |
